Hematólogo en Guadalajara - Dr Jorge Lozano Valdivia

Home
Hematólogo en Guadalajara - Dr Jorge Lozano Valdivia

Hematólogo egresado de la Universidad de Guadalajara, Certificado por el Consejo Mexicano de Hemato

15/06/2025

12/06/2025

12/12/2024

ASH 2024

21/06/2024

Today’s EHA is on the diagnostic workup of unexplained , clonal cytopenia of undetermined significance and idiopathic cytopenia of undetermined significance .

Can you fill in A, B & C? Share your answers below or come back tomorrow for the answer.

Interested in ? Listen to our podcast featuring Prof Helen Papadaki (University of Crete, Greece), who discusses the link between clonal hematopoiesis and the risk of developing MDS or AML.

Find it on major podcast platforms or here on the : https://ehacampus.ehaweb.org/ilp/pages/mediacontent.jsf?mediaId=585569&catalogId=355089&menuId=1106&client=

What did you think of this microlearning experience? Help EHA by filling this one-minute survey: https://wkf.ms/3Pdq1uw ‏‎ ‎

14/06/2024

Hace falta sumar los esfuerzos en la sociedad para generar la cultura de donación de sangre voluntaria

18/05/2024

Recombinant ADAMS13 Treatment for Congenital Thrombotic Thrombocytopenic Purpura

Congenital thrombotic thrombocytopenic purpura (TTP) is a rare disease caused by a severe hereditary deficiency of ADAMS13, which normally cleaves von Willibrand factor (VWF). With the accumulation of multimers of VWF with high platelet-binding activity, congenital TTP often manifests as thrombocytopenia since platelets are consumed in forming micro-clots, which may lead to organ failure or even death. Standard treatment involves ADAMS13 replacement from donor-derived plasma and/or plasma products. In November 2023, recombinant ADAMS13 (rADAMS13) was approved by the US Food and Drug Administration for congenital TTP treatment; an encouraging interim analysis from a phase 3, multinational, open-label, crossover trial of rADAMS13 treatment was recently published. Briefly, 48 adults and children with congenital TTP were randomized 1:1 to receive either rADAMS13 or standard therapy as prophylaxis for the first 6-month block; in the second 6-month block, the randomization blocks were switched (i.e. crossed-over); and in the third 6-month block, all patients received rADAMS13. None of the patients receiving rADAMS13 had an acute TTP event compared to one event in a patient receiving standard therapy. On average, ADAMS13 activity returned to 100% normal levels under rADAMS13 therapy compared to 19% with standard therapy. In addition, 9% of patients experienced mild or moderate adverse events while receiving rADAMS13 compared to 48% with standard therapy. The risk of immunogenicity appears to be low, but 14 patients are continuing in the trial to continue to monitor the safety and efficacy of rADAMS13.
https://transfusionnews.com/2024/05/15/recombinant-adams13-treatment-for-congenital-thrombotic-thrombocytopenic-purpura/

10/04/2024

📚 New course out on and !

Learn about the overlapping characteristics of Ph-neg MPN & MDS, and other disorders. The course covers different perspectives, highlighting commonalities and differences with MPN and MDS.

Find it on : https://ehaedu.org/comm_diff_MDSMPN

Address

Opening Hours

Monday	08:00 - 20:00
Tuesday	08:00 - 20:00
Wednesday	08:00 - 20:00
Thursday	08:00 - 20:00
Friday	08:00 - 20:00
Saturday	09:00 - 15:00

Telephone

+523326968101

Website

http://www.hematologoenguadalajaradrjorgelozano.com/

Alerts

Be the first to know and let us send you an email when Hematólogo en Guadalajara - Dr Jorge Lozano Valdivia posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Hematólogo en Guadalajara - Dr Jorge Lozano Valdivia:

Shortcuts

Address
Telephone
Opening Hours
Alerts
Contact The Practice
Claim ownership or report listing

Want your practice to be the top-listed Clinic?

Country:

City: